Disease Diagnosis TRIZ Cases

A blood test measures specific protein expression levels to screen for Alzheimer's disease presence.

IgE antibodies repolarize macrophages from quiescent states to anti-tumor phenotypes, enhancing immune response against cancer.

A disposable cartridge collects menstrual fluid samples for wireless biomarker analysis.

Targeting transglutaminase 6 resolves the limitation of TG2 assays by detecting autoantibodies linked to gluten-sensitive ataxia and neuropathy.

Analyzes patient blood samples to identify relevant peer-reviewed research publications based on angiogenic regulator levels.

A molecularly imprinted polymer layer on a metal electrode selectively binds Alzheimer's disease biomarkers in breath samples.

Human transglutaminase enables rapid antibody detection in intestinal biopsies, replacing 72-hour incubation with a 20-minute chromogenic test.

An oral rinse assay measuring soluble CD44 and total protein levels resolves low sensitivity in existing biomarkers by establishing precise reference ranges.

Serum pancreatic stone protein measurement enables rapid infectious peritonitis detection without invasive fluid sampling.

A multi-protein signature predicts type 2 diabetes status through logistic regression analysis of biological samples.

Immunoassays measure otolin-1 and prestin concentrations in serum to diagnose inner ear damage before audiometric tests reveal hearing loss.

HK1 and KLHL12 autoantigens improve diagnostic sensitivity for AMA-negative patients through segmented testing.

Mass spectrometry quantifies HbA1c and HbA0 ratios in serum samples to resolve sensitivity limits of traditional glycemic monitoring tests.

A seeding assay using mutated recombinant alpha-synuclein substrates accelerates aggregate detection through coaggregation and fluorescence.

A detection method plots antigen binding curves to determine antibody presence via secondary parameters.

Elevating intracellular cAMP levels in astrocytes via receptor agonists or phosphodiesterase inhibitors to reduce cell swelling and cytoplasmic excitability.

Measuring plasma macrophage migration inhibitory factor concentration enables early acute coronary syndrome detection within four hours of symptom onset.

Multi-analyte urine testing differentiates volume-dependent from ischemic acute kidney injury, preventing harmful fluid administration in non-responsive cases.

A cytokine score predicts patient prognosis from measured concentrations.

A B-cell ELISPOT assay quantifies memory B cells producing donor-specific antibodies using HLA multimers.

A fluorescent cyclic RGD peptide probe targets integrin alpha v beta 3 on angiogenic vessels to visualize retinochoroidal neovascularization lesions.

A mutant therapeutic antibody enables specific detection of anti-drug antibodies in patient samples.

Detecting DSG2 autoantibodies resolves low sensitivity in current genetic testing by correlating biomarker levels with disease burden.

Intermittent anti-CLECL1 antibody dosing reduces treatment cost and resistance while controlling disease progression.

Segmenting circulating tumor cells by nuclear diameter improves visceral metastasis prediction accuracy while reducing assay complexity.

Quantifying peripheral blood immune markers detects Alzheimer's disease earlier than clinical assessments, bypassing the blood-brain barrier.

Combining DAS, N3AP, and CA125 biomarkers captures early-stage cases missed by single markers to improve diagnostic sensitivity.

An extended cardiovascular disease risk panel combines traditional markers with HDL subpopulations and inflammatory indicators for detailed metabolic assessment.

Urinary hepcidin to creatinine ratio predicts acute kidney injury risk following cardiopulmonary bypass surgery.

Urinary protein biomarkers replace invasive endoscopy to enable simple, high-sensitivity detection of colorectal cancer and adenoma.

Measuring IKZF1 and IKZF3 protein levels predicts treatment efficacy, replacing cumbersome live cellular assays.

Photometric measurement of total cholesterol, hydroperoxides, and antioxidant capacity enables calculation of the OBRI cardiovascular risk index.

Measuring urinary apolipoprotein E concentration enables accurate risk assessment for diabetic nephropathy progression.

Extracting specific biomarkers from blood vesicles replaces invasive brain tissue analysis to improve diagnostic accuracy.

Detecting anti-SLC3a2 autoantibodies in patient serum enables early glioblastoma identification through immunological recognition.

Altered recombinant Fc domain epitopes distinguish disease-specific rheumatoid factor reactivity patterns for accurate diagnosis.

Hyperoxic incubation amplifies glucose uptake differences between cancer and healthy cells, resolving detection accuracy limits for EpCAM-negative tumors.

Predict atopic dermatitis propensity using skin surface biomarkers like hBD1 and IL1RA, addressing insufficient understanding of emollient mechanisms.

Combining specific biomarkers achieves high diagnostic accuracy for early infection detection.

Combining procalcitonin thresholds with NT-proBNP markers resolves insufficient prediction accuracy for adverse outcomes in acute coronary syndrome patients.

Analyzes exosomal biomarkers in liquid biopsies to enable early-stage lung cancer detection without invasive tissue sampling.

Specific CDR sequences in antibody 816C12 resolve false positive and negative rates, improving IGF-1R scoring accuracy for targeted therapy selection.

High-sensitivity flow cytometry detects extracellular vesicles expressing CD31, CD105, or CD64 markers to classify patient risk levels.

A microfluidic exosome profiling platform integrates isolation and proteomic analysis to detect specific biomarkers directly from plasma samples.

Segmented SOX2 immune biomarker testing resolves the trade-off between predictive accuracy and patient selection complexity in non-small cell lung cancer.

A method estimates coagulation test results from underfilled patient samples by applying percent-fill-dependent correction factors to measured values.

Detecting occludin fragments in blood assesses blood-brain barrier damage to guide safe thrombolysis treatment decisions.